Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Rapid Result Test for Complicated Urinary Tract Infections Proves Superior to Standard Urine Culture

By LabMedica International staff writers
Posted on 18 May 2022

Complicated urinary tract infections (cUTIs) are a significant burden on individual health and healthcare resources that must be diagnosed and treated early and accurately to reduce the risk of poor outcomes. More...

Now, an advanced rapid result test better addresses polymicrobial infections in difficult cases, where bacterial interactions can impact antibiotic resistance.

Pathnostics’ (Irvine, CA, USA) Guidance UTI testing combines PCR and Pooled Antibiotic Susceptibility Testing (P-AST™) for precision diagnostic testing with rapid results for the management of complicated, recurrent or persistent UTIs and elevated risk patients. Guidance UTI provides personalized results in less than one day from receipt at lab, while culture can take 3-5 days, reducing the need for empiric therapy and supporting antibiotic stewardship initiatives. Results are summarized in an easy- to-read report showing therapy options based on the patient’s individual infection.

Real world evidence has shown that Guidance UTI testing is associated with reductions in critical adverse outcomes, healthcare resource utilization and cost for cUTI compared to standard urine culture (SUC). A comparative analysis designed to examine outcomes of one year of cUTI treatment guided by either Guidance UTI or SUC found 44% lower total costs and 77% lower clinically-advanced costs with Guidance UTI versus SUC. The analysis also found that cUTIs in the Guidance UTI cohort were likelier to be managed successfully as outpatients.

"We conducted this analysis because evidence-based testing is of critical importance to diagnostic laboratories in order to improve the quality of patient care and ensure better use of healthcare resources," said Mohit Mathur, SVP of Medical Affairs at Pathnostics. "Our commitment to providing real-world evidence is a key part of our vision to create a new standard of care in UTI testing and our overall mission to pioneer a better future by providing innovative solutions to address diagnostic and therapeutic dilemmas. The findings reinforce the real-world benefits of Guidance UTI's increased sensitivity, reduced time to results, and P-AST results to patients, providers, and the healthcare system."

Related Links:
Pathnostics 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Nucleic Acid Purification Instrument
QIAsymphony Connect
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.